Nano arsenic agent for enhancing pyroptosis of tumor cells as well as preparation method and application of nano arsenic agent
By inhibiting autophagy and enhancing pyroptosis of tumor cells through the nano-arsenic agent AsMn/Dz@BSA-FA, the drug resistance and toxic side effects of traditional liver cancer treatments have been solved. This approach achieves synergistic enhancement of tumor-targeted delivery and immune response, providing a new method for gene therapy of liver cancer.
Patent Information
- Application Number
- CN202410918305.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-08
AI Technical Summary
Traditional treatments for liver cancer have limited efficacy and face challenges such as chemotherapy resistance and adverse drug reactions. ATO induces autophagy in tumor cells while simultaneously inducing pyroptosis, which affects the effectiveness of these treatments. Therefore, it is necessary to develop a tumor-targeted delivery system that inhibits autophagy to enhance tumor cell pyroptosis and immune response.
The nano-arsenic agent AsMn/Dz@BSA-FA is used to activate the DNase Dz by manganese ions to silence the Beclin1 protein, inhibit autophagy, and achieve tumor-targeted delivery by combining with folic acid modification. This enhances the pyroptosis-promoting ability of ATO and activates immune cells to induce immunogenic death.
It significantly enhances tumor cell pyroptosis, improves the treatment effect of liver cancer, reduces toxic side effects on normal tissues, activates the immune response, provides gene therapy ideas, and achieves drug accumulation at the tumor site and systemic anti-tumor immune response.
Smart Images

Figure CN118903045A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of nanomaterials and nanobiomedicine, and specifically relates to a nano arsenic agent for enhancing tumor cell pyroptosis and a preparation method and application thereof. Background Art
[0002] Liver cancer remains a major global health problem, with approximately 860,000 new cases reported each year, and is the third leading cause of cancer-related death. Conventional treatments for liver cancer have limited efficacy and face limitations such as treatment resistance and adverse drug reactions, resulting in stagnant overall survival rates over the past decade. Therefore, innovative treatments are needed to overcome existing treatment bottlenecks and improve the treatment of liver cancer. Chemotherapy is the cornerstone of cancer treatment and exerts anti-tumor effects mainly through the caspase-3 pathway to induce cell apoptosis. However, the emergence of tumor cell-mediated chemotherapy resistance poses a huge challenge, which manifests itself through multiple mechanisms, such as inhibition of intracellular caspase-3 activity and blockade of the caspase-3 signaling cascade. Therefore, there is growing interest in exploring cell death mechanisms other than apoptosis as a strategy for chemosensitization. Pyroptosis is a regulated form of programmed cell death mediated by members of the gasdermin protein family, which has attracted great attention due to its high immunogenicity and strong inflammatory response. However, autophagy is a key regulator affecting cell pyroptosis. Studies have shown that upregulation of autophagy in solid tumors may impair the activation of the caspase-3-GSDME pathway and hinder the activation of pyroptosis.
[0003] Arsenic trioxide (As2O3, ATO) is a traditional Chinese mineral medicine. Studies have shown that ATO has the ability to induce immunogenic death of tumor cells, making "cold" tumors sensitive to immunotherapy. In addition, ATO induces pyroptosis in liver cancer cells expressing GSDME, highlighting its potential as an anti-tumor drug that promotes pyroptosis. However, the clinical application of ATO is subject to some challenges, such as its rapid clearance by the kidneys and the need for frequent administration, as well as significant toxicity associated with systemic distribution. In addition, while inducing pyroptosis, ATO causes cells to produce protective autophagy, thereby weakening pyroptosis. Therefore, it is urgent to construct a tumor-targeted delivery system that inhibits autophagy and enhances ATO-promoted cell pyroptosis. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a nano-arsenic agent for enhancing tumor cell pyroptosis and a preparation method and application thereof, which significantly amplifies the ability of cell pyroptosis and releases a large amount of DAMPs to trigger a powerful systemic anti-tumor immune response.
[0005] To achieve the above-mentioned purpose, the present scheme first provides a nano-arsenic agent for enhancing tumor cell pyroptosis, wherein the nano-arsenic agent comprises arsenic trioxide (ATO), manganese ions, DNA enzyme (Dz), bovine serum albumin (BSA) and folic acid (FA), wherein the arsenic trioxide forms a precipitation complex with the manganese ions, the bovine serum albumin simultaneously encapsulates the precipitation complex and the DNA enzyme, and the folic acid modifies the surface of the bovine serum albumin.
[0006] Preferably, the encapsulation rate of arsenic trioxide is 30-90%.
[0007] Preferably, the particle size of the nano arsenic agent is 100-250 nm.
[0008] Based on a general inventive concept, the present invention also provides a method for preparing a nano-arsenic agent for enhancing tumor cell pyroptosis, comprising the following steps:
[0009] S1. Add bovine serum albumin-folic acid solution and DNase solution, and stir;
[0010] S2. Add manganese ion solution to the system of S1 and stir for the first time, then add arsenic trioxide solution with a pH of 9 and continue stirring, and remove the supernatant by centrifugation to obtain the nano-arsenic agent AsMn / Dz@BSA-FA that enhances tumor cell pyroptosis.
[0011] Preferably, the concentration of the bovine serum albumin and folic acid solution in step S1 is 0.33-1.67 mg / mL.
[0012] Preferably, the stirring temperature in step S1 is 25° C.-37° C., and the stirring time is 1-4 h.
[0013] Preferably, the molar ratio of the DNA enzyme to arsenic trioxide is 0.5-5:8; and the molar ratio of the manganese ion to arsenic trioxide is 1:2.
[0014] Preferably, the manganese ion solution in step S2 is a manganese chloride solution; and the pH is adjusted using a sodium hydroxide solution.
[0015] Preferably, in step S2, the temperature of the first stirring is 25°C-37°C, and the time is 1-4h; the time of the second stirring is 10min; the speed of the centrifugation is 10000-20000rpm, and the time of the centrifugation is 5-20min.
[0016] Based on a general inventive concept, the present invention also provides an application of a nano-arsenic agent that enhances tumor cell pyroptosis in the preparation of an anti-tumor immunotherapy drug.
[0017] Preferably, the tumor includes liver cancer, and the immunotherapy is to inhibit cell autophagy to induce pyroptosis of tumor cells.
[0018] The mechanism by which this protocol inhibits cell autophagy and induces pyroptosis in tumor cells is as follows:
[0019] This scheme provides a Dz gene silencing Beclin1 protein to inhibit autophagy AsMn / Dz@BSA-FA functionalized nanoparticles, which uses folic acid (FA) to modify the nanosystem in a targeted manner, selectively deliver the drug to the treatment site, increase the accumulation of the drug in the tumor site, and reduce the toxic side effects on normal tissues. This nucleic acid drug carrier provides a basis and idea for gene therapy of liver cancer by promoting the targeted delivery of nucleic acid drugs in tumors and inhibiting the growth of tumor cells.
[0020] Bovine serum albumin can stabilize nanoparticles and provide thiol-linked As-S and Mn-S, which is the basis for the "one-pot" preparation of nanoparticles. Manganese ions can activate Dz cleavage and gene silence Beclin1 expression to inhibit autophagy.
[0021] After the drug targets the tumor, autophagy is inhibited by Dz gene silencing, and arsenic trioxide-induced tumor cell pyroptosis is enhanced. Dz can silence Beclin1 and synergize with ATO to enhance the cell's ability to promote pyroptosis. The increase in the level of cell pyroptosis promotes the maturation of DC. As the final effector cells, cytotoxic T lymphocytes and helper T cells are significantly activated, thereby inducing immunogenic death and releasing DAMPs to trigger a powerful systemic anti-tumor immune response, which has an excellent anti-tumor effect in vivo.
[0022] Compared with the prior art, the present invention has the following beneficial effects:
[0023] (1) The AsMn / Dz@BSA-FA functionalized nanoparticles prepared in this scheme are modified with folic acid and have good targeting properties, which can selectively deliver drugs to the treatment site, increase the accumulation of drugs in the tumor site, and reduce the toxic side effects on normal tissues. In addition, Dz gene silencing inhibits tumor cell autophagy, enhances arsenic trioxide-induced tumor cell pyroptosis, and synergizes with ATO to enhance the cell's ability to promote pyroptosis, providing a basis and ideas for gene therapy of liver cancer.
[0024] (2) In this scheme, bovine serum albumin can stabilize the nanoparticles and provide thiol-linked As-S and Mn-S, which is the basis for the "one-pot" preparation of nanoparticles. Manganese ions can activate Dz cleavage and gene silence Beclin1 expression to inhibit autophagy.
[0025] (3) The AsMn / Dz@BSA-FA functionalized nanoparticles prepared in this scheme have good stability in a simulated physiological environment and have a strong protective effect on Dz, which can avoid or reduce its enzymatic hydrolysis in the in vivo environment.
[0026] (4) AsMn / Dz@BSA-FA is more efficient in silencing Beclin1, inhibiting Hepa1-6 cell autophagy and activating immune cells to induce immunogenic death of tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0028] Figure 1 The particle size diagram of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA detected in Experimental Example 1;
[0029] Figure 2 Potential diagrams of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA were detected for Experimental Example 1;
[0030] Figure 3 For Experimental Example 1, the effect of the final concentration of MnCl2 on the particle size and PDI of AsMn@BSAF was detected;
[0031] Figure 4 For Experimental Example 1, the effect of the final concentration of BSA on the particle size and PDI of AsMn@BSA was detected;
[0032] Figure 5 For Experimental Example 1, the effect of the final concentration of ATO on the particle size and PDI of AsMn@BSA was detected;
[0033] Figure 6 For Experimental Example 1, the effect of Dz concentration on the adsorption amount of AsMn / Dz@BSA-FA nanoparticles was detected;
[0034] Figure 7 Elemental analysis diagram of AsMn / Dz@BSA-FA detected in Experimental Example 1;
[0035] Figure 8 This is a graph showing the particle size change of AsMn / Dz@BSA-FA in H2O, 10% FBS and DMEM complete culture medium detected in Experimental Example 1;
[0036] Fig. 9 This is a diagram showing the protective effect of AsMn / Dz@BSA-FA on Dz in Experimental Example 1;
[0037] Fig.10 This is the gel electrophoresis diagram of the detection of Dz cleavage substrate under different metal ion conditions in Experimental Example 1;
[0038] Fig.11 This is a diagram showing the cellular uptake of AsMn / Dz@BSA, AsMn / Dz@BSA-FA and AsMn / Dz@BSA-FA+FA detected in Experimental Example 2;
[0039] Fig.12 For Experimental Example 3, the cell proliferation of Hepa1-6 cells treated with different preparations at different concentrations was detected;
[0040] Fig.13 The expression of Beclin1, P62 and LC3 proteins after treatment in each group was detected in Experimental Example 4;
[0041] Fig.14 The LDH release obtained by the test in Experimental Example 5;
[0042] Fig.15 For Experimental Example 5, the expression of GSDME-N and caspase-3 proteins was detected;
[0043] Fig.16 The in vivo evaluation efficacy results obtained from the test in Experimental Example 6;
[0044] Fig.17 HE staining results of tumor tissue obtained in Experimental Example 6;
[0045] Fig.18 The ratio of dendritic cells DC and T cells in the tumor tissue obtained in Experimental Example 7 was detected. DETAILED DESCRIPTION
[0046] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0047] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and substance of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention.
[0048] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art; unless otherwise specified, the reagents used in the examples are commercially available.
[0049] Example 1 Preparation of AsMn@BSA Nanoparticles
[0050] Add 2 mL of 1.2 mg / mL BSA solution into a 5 mL beaker, add 200 μL of 50 mM MnCl2 solution and stir at 37 °C for 2 h, add 200 μL of 100 mM ATO solution and continue stirring for 10 min, centrifuge at 16000 rpm for 10 min, remove the supernatant, and obtain AsMn@BSA nanoparticles.
[0051] Example 2 Preparation of AsMn / Dz@BSA Nanoparticles
[0052] Add 2mL of 1.2mg / mL BSA solution into a 5mL beaker, add 200μL of Dz to make the Dz concentration 2μM, stir at 37℃ for 1h, add 200μL of 50mM MnCl2 solution and continue stirring for 2h, add 200μL of 100MmATO solution and continue stirring for 10min, centrifuge at 16000rpm for 10min, remove the supernatant to obtain AsMn / Dz@BSA nanoparticles.
[0053] Example 3 Preparation of AsMn / Dz@BSA-FA Nanoparticles
[0054] S1. Add 2 mL of 1.2 mg / mL BSA and FA solution into a 5 mL beaker, add 200 μL Dz to make the Dz concentration 2 μM, and stir at 37 °C for 1 h.
[0055] S2. Add 200 μL of 50 mM MnCl2 solution to the system of S1 and continue stirring at 37°C for 2 h. Add 200 μL of 100 mM ATO solution and continue stirring for 10 min. Centrifuge at 16000 rpm for 10 min and remove the supernatant to obtain AsMn / Dz@BSA-FA nanoparticles.
[0056] Experimental Example 1: Characteristics of the Nanoparticles Prepared in Examples 1-3
[0057] (1) Particle size and potential: The particle size and potential of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA were measured respectively. The measurement method was as follows: the sample solution was placed in a Marlven Nano ZS instrument and the particle size and potential were measured using a dynamic light laser scattering method. The temperature of the measurement cell was set at 25 °C and each sample was operated in parallel for 3 times.
[0058] The results are as follows Figure 1-2 As shown, Figure 1 The particle size diagram of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA. Figure 2The potential diagrams of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA show that: the particle size of AsMn@BSA is 160nm and the potential is -13.6mV; the particle size of AsMn / Dz@BSA is 200nm and the potential is -16.6mV; the particle size of AsMn / Dz@BSA-FA is 200nm and the potential is 16.56mV.
[0059] (2) The effects of the final concentrations of MnCl2, BSA, and ATO on the particle size and polydispersity index (PDI) of the AsMn@BSA nanoparticles prepared in Example 1 were investigated:
[0060] ① Exploration of the effect of the final concentration of MnCl2 on the particle size and PDI of AsMn@BSA. The measurement method is as follows: 2mL of 1.2mg / mL BSA solution was added to a 5mL beaker, and 200μL of MnCl2 solution with concentrations of (50, 100, 200, 300, 400mM) was added to make the final concentrations (4.17, 8.33, 16.67, 25 and 33.33mM) and stirred for 2h. Then 200μL of 100mM ATO solution was added and continued to stir for 10min. Centrifuge at 16000rpm for 10min, remove the supernatant, take the precipitate and add ultrapure water to re-dissolve it to obtain AsMn@BSA. The effect of the final concentration of MnCl2 on the preparation of nanoparticles was investigated by particle size and PDI. The results are as follows Figure 3 As shown, Figure 3 The figure shows the effect of the final concentration of MnCl2 on the particle size and PDI of AsMn@BSA. The results show that when the final concentration of MnCl2 is 4.17mM, the particle size is less than 200nm and the PDI is less than 0.2, indicating that the dispersibility is best at this concentration.
[0061] ②Exploration of the effect of BSA final concentration on the particle size and PDI of AsMn@BSA. Measurement method: 2 mL of BSA solution with concentrations of (0.8, 1.2, 1.6, 2.0 mg / mL) to make the final concentration of (0.33, 0.67, 1, 1.33 and 1.67 mg / mL) was added to a 5 mL beaker, 200 μL of 50 mM MnCl2 solution was added and stirred for 2 h, and then 200 μL of 100 mM ATO solution was added and continued to stir for 10 min. Then, centrifuged at 16000 rpm for 10 min, the supernatant was removed, and the precipitate was re-dissolved in ultrapure water to obtain AsMn@BSA. The effect of the final concentration of BSA on the preparation of nanoparticles was investigated by particle size and PDI. The results are shown in Figure 4 As shown, Figure 4The effect of BSA final concentration on the particle size and PDI of AsMn@BSA was studied. The results showed that when the final concentration of BSA was 1 mg / mL, the particle size and PDI were relatively stable. Therefore, a BSA concentration of 1 mg / mL was selected for subsequent preparation.
[0062] ③The effect of the final concentration of ATO on the particle size and PDI of AsMn@BSA. The measurement method is as follows: 2mL of 1.2mg / mL BSA solution is added to a 5mL beaker, 200μL of 50mM MnCl2 solution is added and stirred for 2h, and then 200μL of ATO solution with concentrations of (50, 100, 150, 200mM) is added to make the final concentrations (4.17, 8.33, 12.5 and 16.67mM) respectively. After stirring for 10min, centrifuge at 16000rpm for 10min, remove the supernatant, take the precipitate and add ultrapure water to re-dissolve, and AsMn@BSA is obtained. The effect of the final concentration of ATO on the preparation of nanoparticles is investigated by particle size and PDI. The results are shown in Figure 5 As shown, Figure 5 The effect of ATO final concentration on the particle size and PDI of AsMn@BSA. The results showed that when the final ATO concentration was 8.33 mM, the PDI dropped sharply and then gradually increased. Although the particle size was the smallest when the ATO concentration was 4.17 mM, the PDI was too large, so 100 mM was selected for subsequent preparation.
[0063] (3) Investigate the effect of Dz dosage concentration on the adsorption amount of AsMn / Dz@BSA-FA nanoparticles prepared in Example 3: Add 2mL of 1.2mg / mL BSA and FA solution into a 5mL beaker, add 200μL Dz-FAM (5-carboxyfluorescein) to make its concentration 0.5, 1, 2, 4μM, respectively, stir at 37°C for 1h, add 200μL of 50mM MnCl2 solution and continue stirring for 2h, add 200μL of 100MmATO solution and continue stirring for 10min, centrifuge at 16000rpm for 10min, take the supernatant, analyze the adsorption degree of Dz-FAM by gel electrophoresis, and screen the dosage of Dz. The specific experimental operation of polyacrylamide-urea gel electrophoresis is as follows
[0064] ① Gel preparation: Weigh 48g urea solid, add 10mL 10×TBE, then add 50mL 30% polyacrylamide, heat to 60℃ to dissolve, and store at room temperature for later use. Take 7mL gel stock solution, add 32μL 10% APS and 5μL TEMED, stir evenly, fill the gel plate with liquid, and insert the channel comb;
[0065] ② Loading: After the gel solidifies, gently remove the comb, use the injection solution to absorb 1×TBE buffer to clean the channels, take 15μL of each supernatant and 0.5, 1, 2, 4μM free Dz-FAM solution, mix with 3μL of loading buffer (6× loading buffer), and inject into the gel channels;
[0066] ③ Run the gel: Place the gel in an electrophoresis tank, add 1×TBE buffer, set the voltage to 200V, and stop the electrophoresis after running for 30 minutes;
[0067] ④ Imaging: Take out the gel and display it on a fluorescent imager. Use ImageJ software to perform grayscale analysis on the bands and calculate the encapsulation efficiency.
[0068] The results are as follows Figure 6 As shown, Figure 6 The effect of Dz concentration on the adsorption amount is shown in Figure 2. The results show that the Dz encapsulation efficiency is high in the concentration range of 0.5 to 4 μM Dz, which may be due to the strong metal ion-DNA coordination.
[0069] (4) Morphological Characterization of AsMn / Dz@BSA-FA Nanoparticles Prepared in Example 3
[0070] The sample was dropped onto a 400-mesh copper grid covered with a carbon film, placed in a dryer, and observed under a transmission electron microscope Titan G2-F20 after it was naturally dried. The results are as follows: Figure 7 As shown, Figure 7 This is the elemental analysis diagram of AsMn / Dz@BSA-FA. The results show that the characteristic element As of ATO, the characteristic elements N and P of Dz, and the characteristic element S of BSA can be seen from the elemental spectrum analysis, and the metal element signal of Mn can also be seen.
[0071] (5) Investigating the stability of AsMn / Dz@BSA-FA nanoparticles prepared in Example 3
[0072] AsMn / Dz@BSA-FA was placed in H2O, 10% fetal bovine serum (FBS) and DMEM complete medium containing 10% FBS at 37°C, and the particle sizes of the two were measured at different time points.
[0073] The results are as follows Figure 8 As shown, Figure 8 This is a graph showing the particle size changes of AsMn / Dz@BSA-FA in H2O, 10% FBS and DMEM complete culture medium. It can be seen from the figure that there is no significant change in the particle size of AsMn / Dz@BSA-FA, indicating that AsMn / Dz@BSA-FA has good stability in a simulated physiological environment.
[0074] (6) Investigating the protective effect of AsMn / Dz@BSA-FA nanoparticles prepared in Example 3 on Dz
[0075] According to the preparation method of Example 3, 5-carboxyfluorescein (FAM) labeled AsMn / Dz-FAM@BSA-FA was prepared, diluted 2 times with ultrapure water to make the Dz concentration reach 2μM, and 2μM Dz-FAM solution was prepared separately. Three portions were taken and mixed with 10%, 20%, and 40% FBS in equal volumes, and 13μL of each was placed in a 37°C water bath for 3h, and then heated at 95°C for 10min. 1.5μL 1M EDTA, 0.5μL Tris-HCl (pH 7.4, 300mM) and 10μL 8M urea were added thereto, vortexed and mixed, and then subjected to polyacrylamide gel electrophoresis.
[0076] The results are as follows Fig. 9 As shown, Fig. 9 This is the protective effect diagram of AsMn / Dz@BSA-FA on Dz. It can be seen from the figure that AsMn / Dz@BSA-FA has a strong protective effect on Dz and can avoid or reduce its enzymatic hydrolysis in the body environment.
[0077] (7) Investigate the cleavage of Dz substrate under different metal ion conditions
[0078] The cleavage activity of Dz was detected by gel electrophoresis. Dz (10 μM), substrate chain (10 μM, FAM-labeled) and different concentrations (0, 0.1, 0.2, 0.5, 1 mM) of metal ions (Mg 2+ , Mn 2+ ) was used to initiate the reaction in 50 mM MES buffer (pH 7.0). After incubation for 1 h, urea (8 M) was added to quench the reaction, and the cleaved substrate was separated and analyzed by gel separation. Fig.10 As shown, Fig.10 The gel electrophoresis diagram of Dz cleavage substrate under different conditions shows that intracellular Mg 2+ It can also act as a cofactor for Dz activation, but its efficiency is relatively low. At physiological concentration (1 mM), the cleavage rate after 1 hour of reaction is only ~50%. 2+ The addition of Mn significantly enhanced the cleavage activity of Dz. 2+ Under the conditions of , the lysis rate reached ~80%.
[0079] Experimental Example 2 Investigating the in vitro targeting of AsMn / Dz@BSA and AsMn / Dz@BSA-FA
[0080] Hepa1-6 cells were grown in 6-well plates at 2 × 10 5The cells were cultured overnight at a density of 100 cells / well and then treated with AsMn / Dz@BSA (Example 2), AsMn / Dz@BSA-FA (Example 3), and AsMn / Dz@BSA-FA (Example 3) + FA (1 mM, 1 mL). After incubation for 4 h, the cells were washed three times with PBS, and all cells were digested and resuspended in PBS for quantitative analysis by flow cytometry. In addition, confocal laser scanning microscopy was used to observe the uptake of cells in each group.
[0081] The results are as follows Fig.11 As shown, Fig.11 The figure shows the cell uptake of each preparation. Compared with the AsMn / Dz@BSA group, the fluorescence intensity of the AsMn / Dz@BSA-FA group was significantly enhanced, showing the targeting ability. On the other hand, free FA pretreatment completely eliminated FA-mediated delivery. Overall, the flow cytometry results were consistent with the CLSM results.
[0082] Experimental Example 3 Investigating the cytotoxicity of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA nanoparticles on Hepa1-6 cells
[0083] Hepa1-6 cells were seeded in 96-well plates at a density of 5 × 10 4 cells / mL, incubated overnight to adhere to the wall. Then different concentrations of ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA were added and incubated for 48 hours, 10μL CCK8 solution was added to each well, incubated at 37℃ for 2 hours, and finally the absorbance of each well at 490nm was measured by an ELISA instrument to calculate the cell viability.
[0084] The results are as follows Fig.12 As shown, Fig.12 The cytotoxicity of each preparation on Hepa1-6 cells. It can be seen from the figure that after 48 hours of treatment with different preparations at different drug concentration gradients, the cell viability decreased in a dose-dependent manner, and at each concentration, AsMn / Dz@BSA-FA showed stronger cytotoxicity than free ATO, AsMn@BSA and AsMn / Dz@BSA.
[0085] Experimental Example 4: Inhibition of autophagy in Hepa1-6 cells by AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA nanoparticles
[0086] Hepa1-6 cells were cultured at 2×10 5Each well was inoculated into a 6-well plate and incubated overnight. After it adhered to the wall, the culture medium was discarded and washed twice with PBS. Each well was treated with Control, ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA respectively and cultured in a cell culture incubator for 48 hours. The expression of Beclin1, P62 and LC3 proteins was detected by Western blot experiment. The specific operation steps are as follows:
[0087] ① Protein sample extraction and treatment: After the cell incubation is completed, the culture medium is discarded, the cells are washed with PBS 2-3 times, 200 μL RIPA cell lysis buffer (containing 1% PMSF) is added to lyse the cells, the cells are scraped with a 200 μL tip, the cell lysate is collected and transferred to a 1.5 mL centrifuge tube, vortexed thoroughly, lysed at 4°C for half an hour, and vortexed every 10 minutes. After the end, centrifuge at low temperature (10000rpm, 15min, 4°C), collect the protein and store it in a -80°C refrigerator for standby use. According to the instructions of the BCA protein kit, a protein standard curve is established, and the concentration of the protein sample is determined, and it is diluted to the same concentration, and the two are mixed at a ratio of loading buffer / protein solution (v / v) = 1:4, and the protein is heated at 95°C for 10min to denature it. After the end, the treated protein sample is stored at -80°C for standby use.
[0088] ② Gel electrophoresis and transfer: Install the glass plate for gel preparation, prepare the separation gel according to the instructions of the kit, fill the glass plate with gel to a certain height, slowly add ultrapure water to press the gel, let it stand for about 30 minutes, wait for a clear boundary between water and separation gel (i.e., the separation gel solidifies), pour out the upper layer of water, and dry it with filter paper. Prepare concentrated gel, fill it above the separation gel, insert the comb immediately, wait for the concentrated gel to solidify, and store it at 4°C overnight. Insert the gel into the electrophoresis tank, add an appropriate amount of 1× electrophoresis fluid, pull out the comb vertically, and use a syringe to absorb the electrophoresis fluid and gently rinse the channel. Take 10μL of protein sample for sample loading, add 5μL of Marker to the leftmost loading hole, run the gel at 80V voltage for about 20min, wait for the protein to run from the concentrated gel to the separation gel, convert the voltage to 120V, and stop the electrophoresis when the bromophenol blue reaches the bottom of the gel after 1h. Take out the gel, cut off the excess gel, retain the target protein part, cut a 0.45μm PVDF membrane that is slightly larger than the gel area, soak it in methanol for 1 min, put sponge, filter paper, gel, PVDF membrane, filter paper, sponge in the sample clamp in order, place it in the transfer device, put it in an ice box, add transfer solution, set the current to 200mA, and transfer at 4℃ for 1h.
[0089] ③ Antibody incubation and development: After the transfer, take out the PVDF membrane and immerse it in 5% skim milk, place it on a shaker at room temperature for 1.5 hours, and after the blocking, add the primary antibody (prepared with 5% skim milk) and incubate it at 4°C overnight. After the incubation, wash the PVDF with PBST 3 to 4 times, 10 minutes each time, add the HRP-labeled secondary antibody, incubate at 37°C for 1 hour, and wash it with PBST 3 to 4 times, 10 minutes each time. Finally, incubate the PVDF with ECL developer and place it in a developer for imaging analysis.
[0090] The results are as follows Fig.13 As shown, Fig.13 The expression of Beclin1, P62 and LC3 proteins after treatment in each group. It can be seen from the figure that compared with ATO and AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA can effectively silence Beclin 1, and AsMn / Dz@BSA-FA is more efficient in silencing Beclin1. In addition, Beclin 1 silencing significantly increased the expression of P62 protein and LC3-II, indicating that AsMn / Dz@BSA-FA can inhibit autophagy in Hepa1-6 cells.
[0091] Experimental Example 5: Investigation of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA nanoparticles inducing pyroptosis in Hepa1-6 cells
[0092] (1) LDH release
[0093] Hepa1-6 cells were cultured at 5×10 4 / mL were inoculated in a 96-well plate and treated with Control, ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA for 48 h. The cell supernatant was collected and the LDH release was detected using an LDH kit.
[0094] Fig.14 The figure shows the release level of LDH in each group after treatment. Compared with the control group, the release of LDH in the cell supernatant of the drug-treated group was significantly increased, and the release of the AsMn / Dz@BSA group was more significant than that of the AsMn@BSA group, indicating that Dz silencing Beclin1 protein inhibits autophagy and enhances pyroptosis.
[0095] (2) Expression of GSDME-N and caspase-3
[0096] Hepa1-6 cells were cultured at 2×10 5Each well was inoculated into a 6-well plate and incubated overnight. After it adhered to the wall, the culture medium was discarded and washed twice with PBS. Each well was treated with Control, ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA respectively and cultured in a cell culture incubator for 48 hours. The expression of GSDME-N and caspase-3 proteins was detected by Western blot.
[0097] Fig.15 The graph shows the expression of GSDME-N and caspase-3 proteins after treatment in each group. It can be seen from the figure that increased expression of cleaved-caspase3 and GSDME-N was observed in ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA. The upregulation of GSDME-N in the AsMn / Dz@BSA group was more significant than that in ATO and AsMn@BSA, suggesting that the addition of Dz can enhance the apoptosis-promoting ability of ATO.
[0098] Experimental Example 6 In vivo antitumor activity of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA nanoparticles
[0099] (1) Establishment of tumor-bearing mouse model: Hepa1-6 cells growing logarithmically were collected and dispersed in PBS at a cell density of 2×10 7 The cell suspension was then mixed with an equal volume of Matrigel and injected subcutaneously into the right axilla of C57 mice at a dose of 100 μL per mouse.
[0100] (2) When the tumor volume of the tumor-bearing mice reaches 100 mm 3 The mice were randomly divided into 5 groups, 5 mice in each group, and 100 μL PBS, ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA were injected into the tail vein on days 0, 3 and 6, respectively. The dosage of each reagent was ATO: 1 mg / kg. The length and width of the tumor were measured every two days during the treatment, and the tumor volume was calculated to draw a relative growth curve of the tumor volume. Tumor volume calculation formula: V = length × width 2 / 2, on the 20th day, the mice were killed, the tumors were removed and weighed, and the tumor tissues and major organs were stained with hematoxylin and eosin (HE).
[0101] Fig.16 The curves of tumor volume changes after tail vein injection of PBS, ATO, AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA respectively. It can be seen from the figure that PBS tumor grows the fastest, and all drug groups can significantly inhibit tumor growth, among which AsMn / Dz@BSA-FA has the most significant inhibitory effect.
[0102] Fig.17 This is the HE staining picture of tumor tissue. It can be seen from the picture that the cells in the AsMn / Dz@BSA-FA group were obviously necrotic and the cell nuclei were reduced, showing the most significant anti-tumor effect.
[0103] Experimental Example 7 Investigation of the in vivo immunological mechanism of AsMn@BSA, AsMn / Dz@BSA and AsMn / Dz@BSA-FA nanoparticles
[0104] After treatment, flow cytometry was used to detect the activation of DCs and T cells in tumor tissues. Specific measurement method: Place a 40μM cell strainer on a 6-well plate, add 1mL PBS to wet the strainer, take a portion of fresh mouse tumor, cut it into pieces appropriately, and place it on the cell strainer. Take out the piston of a 2mL sterile syringe to grind the tumor fragments, and add PBS to rinse repeatedly. When there are no obvious fragments of the tumor, collect the single cell suspension in the well into a 15mL sterile centrifuge tube, centrifuge at 1000rpm for 5min, discard the supernatant, and add an appropriate amount of 1× red blood cell lysis buffer to the cell pellet. Let it stand at room temperature for 3-5min, centrifuge at 1000rpm for 5min, discard the supernatant, and repeat several times until the supernatant is no longer red. Add PBS to wash once, add 200μLCD16 / 32 antibody to each group for blocking, and incubate at 4℃ for 10min. Wash once with PBS, resuspend the cells with 1 mL PBS, and add fluorescently labeled antibodies (anti-CD11c-APC, anti-CD86-PE, anti-CD3-FITC, anti-CD4-APC, anti-CD8-PE) to each tube. Set up blank tubes and single-stained tubes. Incubate at 4°C in the dark for 20 minutes, centrifuge at 1000 rpm for 5 minutes to collect the cells, wash twice with PBS, resuspend in 1 mL PBS, and finally detect each sample using flow cytometry.
[0105] Fig.18 The ratio of DCs and T cells in tumor tissues of each group. It can be seen from the figure that compared with the control group, after AsMn / Dz@BSA and AsMn / Dz@BSA-FA treatment, the number of activated DC cells (CD86 + CD11c + ) increased significantly, which was positively correlated with the level of cell pyroptosis. Therefore, the increase in the level of cell pyroptosis promoted the maturation of DCs. As the final effector cells, cytotoxic T lymphocytes (ctl, CD3 + CD8 + T cells) and helper T cells (Ths, CD3 + CD4 + T cells) were significantly activated.
[0106] A person skilled in the art should understand that the discussion of any of the above embodiments is merely illustrative and is not intended to imply that the scope of protection of the present application is limited to these examples. In line with the concept of the present application, the technical features in the above embodiments or different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of different aspects of one or more embodiments of the present application as described above, which are not provided in detail for the sake of simplicity.
[0107] The above is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments. For those skilled in the art, improvements and changes obtained without departing from the technical concept of the present invention should also be regarded as the protection scope of the present invention.
Claims
1. A nano-arsenic agent for enhancing tumor cell pyroptosis, characterized in that: The nano arsenic agent comprises arsenic trioxide, manganese ions, DNA enzyme, bovine serum albumin and folic acid. The arsenic trioxide forms a precipitation complex with the manganese ions, the bovine serum albumin simultaneously encapsulates the precipitation complex and the DNA enzyme, and the folic acid modifies the surface of the bovine serum albumin.
2. The nano-arsenic agent for enhancing tumor cell pyroptosis according to claim 1, characterized in that: The particle size of the nano arsenic agent is 100-250nm.
3. The nano arsenic agent for enhancing tumor cell pyroptosis according to claim 1, characterized in that: The encapsulation rate of arsenic trioxide is 30-90%.
4. A method for preparing a nano-arsenic agent for enhancing tumor cell pyroptosis according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1. Add bovine serum albumin and folic acid solution, add DNase solution, and stir; S2. Add manganese ion solution to the system of S1 and stir for the first time, then add arsenic trioxide solution with a pH of 9 and continue stirring, and remove the supernatant by centrifugation to obtain the nano-arsenic agent AsMn / Dz@BSA-FA that enhances tumor cell pyroptosis.
5. The preparation method according to claim 4, characterized in that: The concentration of the bovine serum albumin-folic acid solution in step S1 is 0.33-1.67 mg / mL; the stirring temperature in step S1 is 25° C.-37° C., and the stirring time is 1-4 h.
6. The preparation method according to claim 4, characterized in that: The molar ratio of the DNA enzyme to arsenic trioxide is 0.5-5:8; the molar ratio of the manganese ion to arsenic trioxide is 1:
2.
7. The preparation method according to claim 4, characterized in that: In the step S2, the manganese ion solution is a manganese chloride solution; and the pH is adjusted with a sodium hydroxide solution.
8. The preparation method according to claim 4, characterized in that: In the step S2, the temperature of the first stirring is 25°C-37°C, and the time is 1-4h; the time of the second stirring is 10min; the speed of the centrifugation is 10000-20000rpm, and the time of the centrifugation is 5-20min.
9. Use of the nano arsenic agent for enhancing tumor cell pyroptosis as claimed in claims 1-3 or the nano arsenic agent prepared by the preparation method as claimed in any one of claims 4-8 in the preparation of anti-tumor immunotherapy drugs.
10. The use according to claim 9, characterized in that: The tumor includes liver cancer, and the immunotherapy is to inhibit cell autophagy and induce pyroptosis of tumor cells.
